

1 **Public health relevant consequences of the COVID-19 pandemic on malaria in sub-**
2 **Saharan Africa: A scoping review**

3 *Anna-Katharina Heuschen^{1*}, Guangyu Lu², Oliver Razum³, Alhassan Abdul-Mumin⁴, Osman*

4 *Sankoh^{1,5,6}, Lorenz von Seidlein⁷, Umberto D`Alessandro⁸, Olaf Müller¹*

5 *Corresponding author

6 1 Institute of Global Health, Medical School, Ruprecht-Karls-University Heidelberg,
7 Germany

8 2 Department of Public Health, Medical College, Yangzhou University, China

9 3 Department of Epidemiology and International Public Health, School of Public Health,
10 Bielefeld University, Germany

11 4 University for Development Studies, School of Medicine, Department of Paediatrics
12 and Child Health, Tamale, Ghana

13 5 Statistics Sierra Leone, Tower Hill, Freetown, Sierra Leone

14 6 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand,
15 Johannesburg, South Africa

16 7 Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
17 Mahidol University, Bangkok, Thailand

18 8 MRC The Gambia

19

20

21

22

23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24

25 **Abstract**

26 *Background:* The COVID-19 pandemic has resulted in unprecedented challenges to
27 health systems worldwide, including the control of non-COVID-19 diseases. Malaria cases and
28 deaths may increase due to the direct and indirect effects of the pandemic in malaria endemic
29 countries, particularly in sub-Saharan Africa (SSA).

30 *Objectives:* This scoping review aims to summarize information on public health
31 relevant effects of the COVID-19 pandemic on the malaria situation in SSA.

32 *Methods:* Review of publications and manuscripts on preprint servers, in peer-reviewed
33 journals and in grey literature documents from December 1, 2019, to June 9, 2021. A structured
34 search was conducted on different databases using predefined eligibility criteria for the
35 selection of articles.

36 *Results:* A total of 51 papers have been included in the analysis. Modeling papers have
37 predicted a significant increase in malaria cases and malaria deaths in SSA due to the effects of
38 the COVID-19 pandemic. Many papers provided potential explanations for expected COVID-
39 19 effects on the malaria burden; these ranged from relevant diagnostical and clinical aspects,
40 to reduced access to health care services, impaired availability of curative and preventive
41 commodities and medications, and effects on malaria prevention campaigns. Compared to
42 previous years, fewer country reports provided data on the actual number of malaria cases and
43 deaths in 2020, with mixed results. While highly endemic countries reported evidence of
44 decreased malaria cases in health facilities, low endemic countries reported overall higher
45 numbers of malaria cases and deaths in 2020.

46 *Conclusions:* The findings from this review provide evidence for a significant but
47 diverse impact of the COVID-19 pandemic on malaria in SSA. There is the need to further
48 investigate the public health consequences of the COVID-19 pandemic on the malaria burden.

49

50 **Protocol registered on Open Science Framework: DOI 10.17605/OSF.IO/STQ9D**

51

52 **Keywords**

53 COVID-19, coronavirus, malaria, pandemic, sub-Saharan Africa, public health, global health

54

55 **Introduction**

56 The emergence of SARS-CoV-2 in China by the end of 2019 has led to the largest pandemic in
57 recent human history (1, 2). By June 14, 2021, there were some 176 million confirmed cases of
58 COVID-19, including 3.8 million deaths, reported to the World Health Organization (WHO)
59 (3). The COVID-19 epidemic waves show variable dynamics in the different WHO Regions,
60 with the highest burden in the American, European and South-East Asian Regions (3, 4). The
61 latter has recently shown particularly high incidence rates, and India is now reporting the second
62 highest number of confirmed cases after the USA (3). In contrast, the African and the Western
63 Pacific WHO Regions continue to report only relatively low numbers of cases and deaths (3,
64 4).

65

66 It was initially predicted that Africa would be the worst affected region by the COVID-19
67 pandemic because of its weak health systems, prevailing poverty, and the high burden of other
68 infectious diseases (5, 6). However, by the end of 2020, only about 3.5% of the global number
69 of COVID-19 cases and deaths were reported from this continent, which is home to 17% of the
70 world's population (3, 7). Overall, the epidemiology of COVID-19 in Africa remains puzzling
71 (5). By June 14, 2021, there were some 3.6 million COVID-19 cases and 89,000 deaths reported
72 from the entire continent, and most of these were from its northern and southern regions (8, 9).
73 Potential explanations for such a situation are incomplete data due to much lower testing
74 capacities, a significantly younger population, overall lower population mobility, cross-reactive
75 immunity or immunomodulation due to high prevalence of other infectious agents, and effects
76 of public health responses (5, 7, 10). First findings from SARS-CoV-2 seroprevalence surveys

77 support the evidence for significant under-reporting and for a predominance of asymptomatic
78 and mild cases (11, 12). Nevertheless, it appears that the second epidemic wave has hit the
79 African continent more severely than the first one, possibly explained by the emergence of more
80 transmissible SARS-CoV-2 variants (7, 13).

81
82 Globally, malaria is still the most important parasitic disease and responsible for a quarter of
83 all deaths among Under Five children in sub-Saharan Africa (SSA) (14, 15). The efforts for
84 global malaria control and elimination have achieved large successes during the last two
85 decades, but progress has stalled in recent years, and the COVID-19 pandemic could largely
86 reverse the overall trend (16, 17). This review aims to summarize currently available data and
87 understanding of the direct and indirect effects of the COVID-19 pandemic on the malaria
88 burden in SSA.

89
90 **Methods**

91 *Search strategy and selection criteria*

92 Due to the complex topic and the different type of studies available, a scoping review
93 methodology was chosen (18). The study protocol (published on OSF, DOI:
94 10.17605/OSF.IO/STQ9D) complies with the ‘Preferred Reporting Items for Systematic
95 Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) checklist’ (19). The
96 following inclusion criteria were applied: Papers needed to respect the categories of the PICO-
97 framework (**P**roblem: malaria situation; **I**nterest: the public health impact of the COVID-19
98 pandemic; **C**ontext: sub-Saharan Africa) (20). No restrictions regarding the study type and the
99 publication status were applied. Possible languages were English, French and German; papers
100 published between December 1, 2019, and June 9, 2021, were included. In line with the
101 protocol, the search strategy was developed, and the following databases were searched:
102 PubMed; Ovid MEDLINE(R); Web of Science; Biosis Previews; MedRxiv, and The Lancet.

103 Grey literature was included using WHO database and Google Scholar. Three broad blocks of
104 search terms were used: (1) COVID-19, (2) malaria, (3) sub-Saharan Africa. The detailed
105 search strategy is available in appendix 1.


106
107 For the extracted findings two researcher (OM and AH) conducted independently the title
108 screening, then the abstract screening and finally the full text review. The papers selected for
109 full-text reading were assessed for eligibility; ineligible papers did not include information on
110 public health relevant consequences of the COVID-19 pandemic on malaria in SSA. Inclusion
111 decisions depended on whether the paper agreed to the PICo-framework and the formal
112 eligibility criteria. Results were compared after each step for discussion and for reaching a
113 consensus. For the analysis of the finally included papers, a data extraction table was
114 constructed (appendix 2).

115
116 The following information was extracted from the papers: Authors, title, study place, study
117 population, study design and outcome. Moreover, the papers were categorized by study type:
118 modeling study, report (country report, general report, case report), review, opinion paper, and
119 policy guideline. The information content was structured and analyzed around the following
120 themes:

- 121 • Modeled impact of COVID-19 on malaria
- 122 • Diagnostic and clinical aspects
- 123 • Access to health care services
- 124 • Availability of curative and preventive malaria commodities
- 125 • Impact on malaria programs
- 126 • Epidemiologic data from countries

127


128 Based on these findings, a conceptual framework was created, with input from all co-authors
129 (figure 1).



130
131 **Figure 1:** Conceptual framework presenting the different factors resulting from the global
132 COVID-19 pandemic on the malaria situation in SSA.

133
134 **Results**

135 Figure 2 visualizes the study selection process. The initial search produced 851 documents.
136 After removal of 203 duplicates, 648 documents underwent title and abstract screening. After
137 exclusion of 535 documents which did not meet the inclusion criteria, 113 papers were included
138 for full text review. 9 papers were added from reference screening; 71 were excluded as they
139 also did not meet the inclusion criteria. Thus, a total of 51 papers were reviewed (6 modeling
140 studies, 10 country reports, 6 general reports, 1 case report, 9 review papers, 18 opinion papers,
141 and 1 policy guideline).



142

143 **Figure 2:** Study selection process

144

145 *Modeled impact of COVID-19 on malaria*

146 Five papers predicted the evolution of the malaria burden in SSA based on different potential
147 scenarios. Considering primarily a reduced access to effective antimalarial treatment and
148 reduced insecticide-treated mosquito net (ITN) distribution, Weiss et al. predicted in their
149 worst-case scenario (75% less anti-malarial drugs and ITNs) and for the year 2020 that in SSA
150 countries malaria cases would increase by 22% (from 215 to 262 million) and malaria deaths
151 by 99% (from 386,000 to 769,000); the lower access to antimalarial treatment had a larger effect
152 than reduced ITN distribution (21). These estimates mirror those by the WHO, but the authors
153 described the effects of nine different scenarios compared to the effects of three scenarios by
154 Weiss et al. (22). Comparable estimates were published by Sherrard-Smith et al.; for the

155 scenario of complete interruption of ITN distribution and 50% decreased access to
156 antimalarials; they predicted malaria deaths would increase in SSA to 779,000 for the year 2020
157 (23). A further analysis by WHO predicted up to 100,000 additional deaths in 2020 with a 50%
158 lower access to antimalarials (17). However, all these authors emphasized that the projected
159 effects on malaria services and mortality are highly uncertain because these estimates are
160 heavily dependent on how countries respond to the COVID-19 pandemic. Regarding the
161 relative burden of COVID-19 in Africa, one study concluded that the excess Disability-
162 Adjusted Life Years (DALYs) lost by malaria due to COVID-19 may exceed those directly lost
163 due to COVID-19 (24).

164

165 *Diagnostic and clinical aspects*

166 The clinical manifestations of COVID-19 and malaria largely overlap; fever, headache, joint
167 pain, respiratory symptoms, and general weakness are frequently seen with both diseases (25-
168 27). Thus, diagnosis based on symptoms alone can result in inadequate treatment, with
169 potentially harmful consequences. Untreated malaria can be rapidly fatal and COVID-19
170 patients must be quarantined to interrupt community transmission (14, 28). Despite increasing
171 availability of rapid diagnostic tests (RDTs) for malaria in all endemic areas, presumptive
172 diagnosis of malaria is still common in SSA, and the WHO Malaria Technical Guidelines
173 adapted to COVID-19 confirm this situation (29, 30). Initial information available for 2020
174 suggests major disruptions in malaria diagnosis and treatment due to COVID-19 (31, 32).

175

176 Human travel history is important for SARS-CoV-2 and malaria, as for both of them
177 asymptomatic persons can spread and/or maintain transmission of the infectious agent (26).
178 Malaria might have been reduced by the COVID-19 movement restrictions, especially in
179 heterogenous malaria-endemic settings where transmission frequently results from migration
180 flows of infected individuals across different regions (33). Moreover, malaria and SARS-CoV-

181 2 co-infections may be associated with clinical disease modification, although data on this are
182 limited (27, 34-36).

183
184 While symptomatic malaria affects mainly children and younger age groups in endemic areas,
185 COVID-19 affects all age groups but is more frequently symptomatic and severe with
186 increasing age (34). However, in areas of low malaria transmission, the age groups affected by
187 the two diseases largely overlap (37). RDTs are essential for malaria diagnosis in rural SSA
188 and may also become important for COVID-19, as the PCR test capacity is very limited (32).
189 However, the impact of rather low sensitivity and specificity of COVID-19 RDTs is still under
190 intense discussion (27, 38). An additional challenge for differential diagnosis is the increasing
191 frequency of gene-mutated *Plasmodium* parasites, especially in the Horn of Africa, that escape
192 detection by standard RDTs (37).

193
194 The role of antimalarials, e.g. artemisinin derivatives and chloroquine (CQ), in the COVID-19
195 pandemic is complex. Various artemisinin derivatives, artemisinin-based combination therapies
196 (ACTs) as well as CQ have been shown to be effective against SARS-CoV-1 and SARS-CoV-
197 2 *in vitro* (39-42). However, such beneficial effect was not confirmed by several clinical trials
198 (43-46). The wide use of these treatments in highly malaria endemic countries has been
199 suggested to be responsible for the reported low COVID-19 burden in SSA (36, 47). On the
200 other hand, the increased usage of these drugs for COVID-19 prevention and treatment in some
201 malaria endemic countries might have reduced malaria (25). A frequent off-label use of
202 artemisinin-based drugs may also increase the likelihood of emerging drug resistance and thus
203 threatens the most important of the remaining effective antimalarials (33, 48-50).

204

205 ***Access to health care services***

206 The COVID-19 pandemic in SSA endangers access to health care services due to several
207 factors. Direct factors include restricted services and closures of health facilities because of
208 reduced health care worker (HCW) capacity due to lack of personal protective equipment
209 (PPE), stigmatization, fear of getting infected, or absence due to COVID-19 quarantine, disease
210 or death (27, 32, 50, 51). Delayed treatment results in prolonged gametocyte carriage and
211 additional opportunities for transmission.

212

213 Moreover, because of overload of COVID-19 patients and consequently reduced time to
214 manage other diseases, or due to movement and travel restrictions and for fear of becoming
215 infected with COVID-19, sick individuals with diseases other than COVID-19 do no longer
216 attend health facilities (33, 48, 52). As older people fear severe COVID-19 disease and may
217 thus avoid visiting health facilities, this might affect children the most as they depend on their
218 care givers if sick, including for malaria (35, 49). Stay-at-home advices for febrile diseases,
219 especially at the beginning of the pandemic, enhanced such a behavior (17, 33).

220

221 Indirect factors include reduced income during lockdowns due to inability to perform informal
222 work, and subsequently reduced purchasing power (52). The resulting increase in poverty leads
223 to challenges for paying the costs for routine care, drugs, or transportation fees (51).
224 Lockdowns, movement restrictions and border closures further complicate access to health
225 facilities and have also threatened the functioning of malaria surveillance systems (16, 28, 33,
226 51). Institutional mistrust and lack of valid information further reduced visits to health care
227 facilities and reduced uptake of preventive measures; as an example, myths about the spread of
228 COVID-19 via ITNs led to a reduced usage of this essential intervention in Sierra Leone (25).

229

230 *Availability of curative and preventive commodities and medicines*

231 Increased material costs, reluctance of producers to invest, travel restrictions, border closures,
232 and lockdowns resulted in a lower availability of medical malaria products (26, 28, 48). Low-
233 and middle-income countries (LMICs) are disproportionately affected as they essentially rely
234 on importation of these commodities (52). Excessive use of antimalarials for COVID-19
235 prevention and treatment in some regions has led to shortages for their original purpose (17,
236 30). Some international companies switched from the production of malaria products to
237 COVID-19 products (48, 49, 51). Difficult access to health facilities lowered the availability of
238 essential drugs and increased their price, with subsequent increases in purchase and usage of
239 sub-standard drugs and alternative medicines (28, 51-53). In addition, PPE needed for the
240 implementation of different malaria services (e.g. indoor residual spraying of insecticides, IRS)
241 has become scarce and expensive on global markets (17, 54).

242

243 *Impact of the pandemic on malaria programs*

244 The extent of the pandemic's impacts on malaria depends on the timing of its waves. The largest
245 effects may occur if the COVID-19 transmission peaks and the planned malaria campaigns
246 overlap (21, 23, 53, 55). About three quarters of malaria-affected countries reported disruptions
247 of malaria services and programs (17, 32, 33, 50, 53, 56-58). Reallocation of funds from other
248 disease control programs to the control of COVID-19 have been common and pose great
249 problems for malaria control (30, 32, 35, 59, 60). Ongoing malaria programs (e.g. IRS, ITN
250 interventions) need to be adapted to the restrictions associated with COVID-19 control
251 measures, which requires additional financial resources (32, 33, 36). Programs for vulnerable
252 populations living in remote areas are particularly at risk as they strongly depend on logistics
253 and external financing (33, 48). Disrupted ITN programs will lead to increased malaria
254 transmission as 80% of the nets are distributed through mass campaigns (22, 48, 53, 55). IRS
255 campaigns face many challenges as they require direct household contact (33, 50, 57).

256

257 Nevertheless, these challenges have led to new approaches: Benin digitalized its ITN mass
258 distribution campaign using a ‘no touch’ payment for campaign workers. The national strategy
259 was changed from a fixed-point to a door-to-door-distribution procedure, which enabled health
260 workers to provide additional community health education on COVID-19 and other aspects;
261 other countries followed the Benin model and by the end of 2020, 90% of all globally planned
262 malaria prevention campaigns had been implemented (17, 28, 54, 57, 59).

263

264 *Epidemiologic data from countries*

265 Compared to previous years, fewer papers provided data from African countries on the actual
266 number of malaria cases and deaths in 2020. A small study from Sierra Leone reported a
267 significant lower number of malaria outpatient visits in one health facility during the
268 March/April 2020 lockdown period as compared to the same period in 2019 (29). In addition,
269 preliminary national data from Uganda point to a reduction of malaria cases diagnosed in health
270 facilities during the first quarter of 2020 compared to the same period in 2019 (61). Another
271 study from Uganda reported a 54% decrease in visits for malaria treatment of febrile children;
272 visits for antenatal care declined by 26%, restricting the delivery of intermittent preventive
273 malaria treatment in pregnancy (IPTp) (62). In the Democratic Republic of the Congo (DRC),
274 lower attendance to health facilities for malaria treatment ranged from 20% to 90%, depending
275 on local lockdown measures (63). In contrast, a study from one rural district in Zimbabwe
276 reported a large increase in malaria cases in 2020 compared to previous years, which was
277 associated with delayed IRS in 2020 (50). These findings were confirmed by national data from
278 Zimbabwe, which compared the number of malaria cases and deaths in 2020 with those in
279 previous years; in 2020, there was a large excess of reported malaria cases and deaths (27, 64).
280 Moreover, national data from Zambia showed an increase of malaria cases between August
281 2019, and June 2020; however, no data from control periods were provided (65).

282

283 **Discussion**

284 The COVID-19 pandemic has a massive impact on nearly all countries across the world. While
285 the initial spread of SARS-CoV-2 to Africa has been slow and the COVID-19 burden appears
286 to be much lower than in other continents, the pandemic carries a high potential to negatively
287 affect the control of other diseases such as malaria (7). It has already been shown, that the
288 pandemic has resulted in major reductions of the incidence of other respiratory diseases due to
289 various effects (66). Moreover, it has been predicted that the pandemic will result in major
290 disruptions of routine childhood vaccinations, which may cause an increase in vaccine-
291 preventable infectious diseases in SSA (67). Both malaria and COVID-19 affect
292 disproportionately the low socio-economic classes (28, 32, 68). It is possible that the COVID-
293 19 pandemic and its indirect effects, including the measures to contain it, may produce
294 collateral damages similar to those seen six years ago during the West African Ebola epidemic,
295 i.e. a sharp increase of malaria deaths which finally exceeded the direct Ebola mortality (17,
296 36, 69). Thus, understanding how the COVID-19 pandemic affects malaria control measures is
297 of extreme importance for SSA (17, 59).

298
299 Accelerated malaria control efforts since the early 21st century have significantly reduced the
300 malaria burden in Africa and worldwide (17). Control strategies include ITN and IRS
301 interventions, early diagnosis and rapid treatment with ACT, and intermittent preventive
302 treatment for infants, children and pregnant women (14). However, the rate of reduction in
303 malaria morbidity and mortality in SSA has recently stalled, and the initial overall positive trend
304 could be seriously reversed due to the effects of the COVID-19 pandemic as shown in several
305 modelling studies (17, 21-23).

306
307 In accordance with our conceptual framework, four major themes likely play a major role for
308 the effects of the COVID-19 pandemic on malaria in SSA: (1) diagnostic and clinical aspects;

309 (2) access to health care services; (3) availability of curative and preventive malaria
310 commodities; and (4) impact on malaria prevention programs. While diagnostic and clinical
311 aspects will play an obvious role due to the overlapping symptoms of both diseases (27, 70,
312 71), therapeutic aspects related to initial misperceptions regarding the efficacy of certain
313 antimalarials against COVID-19 may have been overemphasized (25, 36). Co-infection with
314 malaria may complicate COVID-19, while immunomodulation caused by previous malaria
315 exposure may result in less severe COVID-19, as previously also shown in other respiratory
316 diseases (72-75). Reduced access to health care services due to direct and indirect effects of the
317 pandemic has a negative impact on access to antimalarial treatment, thus it would likely have a
318 major effect on the malaria burden in endemic countries (17, 49, 53). This will be compounded
319 by the clear negative impact of the pandemic on global supply chains for curative and
320 preventive malaria commodities (48, 52). The consequences of the pandemic for preventive
321 malaria control programs have been much emphasized by many of the reviewed papers and
322 particularly in modeling papers. However, as an effect of such early warnings, country
323 programs and funding for malaria have probably adapted rapidly to the pandemic as early as
324 2020, which may have reduced the modeled impact (28, 59). International actors like the WHO
325 may have contributed to the prevention of some worst-case scenarios by providing adapted
326 malaria strategies and keeping malaria in their priorities (17, 30).

327
328 Until June 2021, only a few reports provided actual epidemiological data on malaria in SSA
329 during the first wave of the pandemic in 2020, thus drawing conclusions on these data might be
330 premature. However, these reports showed that the number of reported malaria cases in Sierra
331 Leone, Uganda and the DRC, what are more highly malaria endemic countries, was much lower
332 than expected (29, 61-63), while the number of reported malaria cases in Zimbabwe and
333 Zambia, that are countries of low endemicity, was higher than in previous years (27, 29, 64,
334 65). It could be speculated that possibly lower access to health care services in combination

335 with impaired malaria surveillance systems may have led to a lower number of reported malaria
336 cases and deaths in these selected highly endemic countries. In the two low endemic southern
337 SSA countries, disruption of malaria control activities within relatively well-functioning health
338 systems, including surveillance activities, may have resulted in a higher number of reported
339 malaria cases and deaths. More information from other African endemic countries is needed to
340 fully assess such developments (59, 76). As the COVID-19 pandemic is far from being under
341 control in most LMICs as new and more infectious SARS-CoV-2 variants are emerging, and as
342 SSA countries have limited access to COVID-19 vaccines, dramatic increases of the malaria
343 burden may occur (59, 77, 78). Although the findings of existing modeling studies are already
344 alarming, the final impact of the pandemic on the malaria burden could be even more devastating
345 (21, 51). Better education, sensitization and de-stigmatization of both diseases is essential,
346 including emphasis on early care seeking behaviour, which needs also more community
347 participation (25, 29). Community health workers should be encouraged to treat all
348 uncomplicated malaria cases in the community and to refer to health facilities only severe cases
349 (51, 79). As 2020 was a year with many planned malaria prevention campaigns, the negative
350 effects of disrupted programs would probably last for some years (21, 23). Fortunately, the
351 international community, including the WHO, acted fast to counteract such developments (17).
352 However, there is the need for more support for SSA countries from the international
353 community and from high income countries (32). Malaria, one of Africa's deadliest diseases
354 which disproportionally affects the most vulnerable population groups, must be kept under
355 control (16, 35, 59).

356

357 **Conclusion**

358 The findings from this review provide evidence for a significant but diverse impact of the
359 COVID-19 pandemic on the malaria burden in SSA. Only results of further studies will enable
360 a full understanding of these developments and its public health consequences. In the meantime,

361 SSA countries need more support from the international community including the urgent
362 delivery of COVID-19 vaccines for high-risk groups.

363

364 **List of abbreviations**

365 ACT: artemisinin-based combination therapy

366 COVID-19: coronavirus disease 2019

367 CQ: chloroquine

368 DRC: Democratic Republic of the Congo

369 HCW: health care worker

370 IPTp: intermittent preventive treatment in pregnancy

371 IRS: indoor residual spraying of insecticides

372 ITN: insecticide-treated mosquito net

373 LMIC: low- and middle-income country

374 PICo: problem, interest, context

375 PPE: personal protective equipment

376 SARS-CoV-2: severe acute respiratory coronavirus type 2

377 SSA: sub-Saharan Africa

378 WHO: World Health Organization

379

380 **Declarations**

381 *Ethics approval and consent to participate*

382 Not applicable

383

384 *Consent for publication*

385 Not applicable

386

387 Availability of data and materials

388 The datasets used and/or analysed during the current study are available from the corresponding
389 author on reasonable request.

390

391 Competing interest

392 The authors declare that they have no competing interests.

393

394 Funding

395 Anna-Katharina Heuschen acknowledges the support by the Else Kröner-Fresenius-Stiftung
396 within the Heidelberg Graduate School of Global Health.

397

398 Authors' contributions

399 AH and OM performed the systematic search and screening. AH wrote the first draft, GL did
400 the methodological foundation, OR drafted the conceptual framework; all authors read,
401 reviewed and approved the final manuscript.

402

403 Acknowledgements

404 Not applicable

405

406 **Appendix**

407

408 Appendix 1: Detailed search strategy

409 *Concept 1: COVID-19*

410 “COVID-19”[ALL] OR “COVID*”[ALL] OR “SARS-CoV-2”[ALL] OR

411 “coronavirus*”[ALL] OR “2019-nCoV disease”[ALL] OR “betacoronavirus”[ALL] OR

- 412 “nCoV”[ALL] OR "COVID-19" [Supplementary Concept] OR "severe acute respiratory
 413 syndrome coronavirus 2"[nm]
 414 *Concept 2: malaria*
 415 “malaria*”[ALL] OR “paludism*”[ALL] OR "Malaria"[Mesh] OR "Malaria/prevention and
 416 control"[MAJR]
 417 *Concept 3: sub-Saharan Africa*
 418 “africa”[ALL] OR “sub-saharan”[ALL] OR “SSA”[ALL] OR “south of the sahara”[ALL] OR
 419 "Africa South of the Sahara"[Mesh]
 420 *Concept 1 AND concept 2 AND Concept 3*

Search number	Query	Sort By	Filters	Search Details	Results	Time
5	#1 AND #2 AND #3	Most Recent	from 2019/12/1 - 2021/6/9	((("COVID-19"[All Fields] OR "covid*" [All Fields] OR "SARS-CoV-2"[All Fields] OR "coronavirus*" [All Fields] OR "2019-nCoV disease"[All Fields] OR "betacoronavirus"[All Fields] OR "nCoV"[All Fields] OR "COVID-19"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) AND ("malaria*" [All Fields] OR "paludism*" [All Fields] OR "Malaria"[MeSH Terms] OR "malaria/prevention and control"[MeSH Major Topic]) AND ("africa"[All Fields] OR "sub-saharan"[All Fields] OR "SSA"[All Fields] OR "south of the sahara"[All Fields] OR "Africa South of the Sahara"[MeSH Terms])) AND (2019/12/1:2021/6/9[pdat])	117	13:34:11
4	#1 AND #2 AND #3	Most Recent		("COVID-19"[All Fields] OR "covid*" [All Fields] OR "SARS-CoV-2"[All Fields] OR "coronavirus*" [All Fields] OR "2019-nCoV disease"[All Fields] OR "betacoronavirus"[All Fields] OR "nCoV"[All Fields] OR "COVID-19"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) AND ("malaria*" [All Fields] OR "paludism*" [All Fields] OR "Malaria"[MeSH Terms] OR "malaria/prevention and control"[MeSH Major Topic]) AND ("africa"[All Fields] OR "sub-saharan"[All Fields] OR "SSA"[All Fields] OR "south of the sahara"[All Fields] OR "Africa South of the Sahara"[MeSH Terms])	121	13:33:52
3	"africa"[ALL] OR "sub-saharan"[ALL] OR "SSA"[ALL] OR "south of the sahara"[ALL] OR "Africa South of the Sahara"[Mesh]	Most Recent		"africa"[All Fields] OR "sub-saharan"[All Fields] OR "SSA"[All Fields] OR "south of the sahara"[All	372,746	13:33:40

				Fields] OR "Africa South of the Sahara"[MeSH Terms]		
2	"malaria*" [ALL] OR "paludism*" [ALL] OR "Malaria" [Mesh] OR "Malaria/prevention control" [MAJR]	OR OR OR and	Most Recent	"malaria*" [All Fields] OR "paludism*" [All Fields] OR "Malaria" [MeSH Terms] OR "malaria/prevention control" [MeSH Major Topic]	104,127	13:33:32
1	"COVID-19" [ALL] OR "COVID*" [ALL] OR "SARS-CoV-2" [ALL] OR "coronavirus*" [ALL] OR "2019-nCoV disease" [ALL] OR "betacoronavirus" [ALL] OR "nCoV" [ALL] OR "COVID-19" [Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2" [nm]	OR OR OR OR OR OR OR OR	Most Recent	"COVID-19" [All Fields] OR "covid*" [All Fields] OR "SARS-CoV-2" [All Fields] OR "coronavirus*" [All Fields] OR "2019-nCoV disease" [All Fields] OR "betacoronavirus" [All Fields] OR "nCoV" [All Fields] OR "COVID-19" [Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2" [Supplementary Concept]	158,835	13:33:26

421

422 Appendix 2: Data extraction table

423 *Table of included studies*

	Authors and year	Title	Study place	Population	Study design	outcome
1.	Aborode et al., 2021 (48)	Fighting COVID-19 at the Expense of Malaria in Africa: The Consequences and Policy Options	sub-Sahara Africa	General population	Opinion paper	Supply chain disruptions; financial shortages; problems for HCWs; changed health seeking behavior; simplified modeling studies, real outcome could be worse
2.	Aikpon et al., 2020 (54)	Digitalized mass distribution campaign of insecticide-treated nets (ITNs) in the particular context of Covid-19 pandemic in Benin: challenges and lessons learned	Benin	General population	Country report	Benin: successful ITN & IRS campaigns, adapted to COVID-19 hygiene measures
3.	Ajayi et al., 2020 (28)	Malaria and COVID-19: commonalities, intersections and implications for sustaining malaria control	Africa	General population	Opinion paper	COVID-19 and malaria are both related with a low socio-economic status; health system and diagnostical challenges; changed health seeking; lack of reliable data due to limited reporting

4.	Amimo et al., 2020a (16)	What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control?	Africa	General population	Report	Clinical and socio-economic aspects; changed health seeking behavior
5.	Amimo et al., 2020b (53)	The potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria control in Africa: a systematic review of modelling studies and population surveys	Africa	General population	Review	Malaria program and ANC disruptions; antenatal care avoidance; increased costs for malaria services
6.	Anjorin et al., 2021 (34)	Comorbidities and the COVID-19 pandemic dynamics in Africa	sub-Sahara Africa	General population	Review	Clinical aspects e.g. overlapping age groups, common symptoms; malaria health service disruptions
7.	Ansumana et al., 2020 (25)	Effects of disruption from COVID-19 on antimalarial strategies	sub-Sahara Africa	General population	Opinion paper	Health system challenges; COVID-19 myths and misinformation affect malaria (reduced ITN usage, increased antimalarials uptake)
8.	Baral et al., 2021 (56) – pre-print	Competing Health Risks Associated with the COVID-19 Pandemic and Response: A Scoping Review	General & Africa	General population	Review	73% disruptions among malaria programs; decreases of malaria diagnoses by 62%; delays in malaria surveillance
9.	Bell and Hansen, 2021 (24) – pre-print	Relative burdens of the COVID-19, malaria, tuberculosis and HIV/AIDS epidemics in sub-Saharan Africa	Sub-Saharan Africa	General population	Modelling study	Low direct COVID-19 impacts in SSA but high indirect impacts on other diseases like malaria
10.	Bell et al., 2020 (61)	Predicting the Impact of COVID-19 and the Potential Impact of the Public Health Response on Disease Burden in Uganda	Uganda	General population	Modelling study	Reduction of malaria cases, admissions, deaths in Uganda
11.	Beshir et al., 2020 (37)	Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the	General & Africa specific	General population	Opinion paper	Diagnostic challenges for malaria due to mutated parasites; clinical challenges and

		COVID-19 Pandemic?				treatment problems
12.	Brooke et al., 2020 (33)	Implementing malaria control in South Africa, Eswatini and southern Mozambique during the COVID-19 pandemic	South Africa, Eswatini, southern Mozambique	General population	Review	Disruptions of malaria programs; diagnostic, health system and socio-economic challenges
13.	Buonsenso et al., 2020 (80)	Child Healthcare and Immunizations in Sub-Saharan Africa During the COVID-19 Pandemic	Sierra Leone	Children under the age of 5	Country report	Reduction in malaria diagnoses (25%-40%); no increases in malaria deaths
14.	Buonsenso et al., 2021 (29)	Management of malaria in children under 5-years-old during COVID-19 pandemic in Sierra Leone: a lesson learned?	Sierra Leone	Children under 5	Country report	Changes in malaria diagnoses at health facilities in context of the lockdown; community education campaign in Sierra Leone; difficult data collection
15.	Burt et al., 2021 (62) – pre-print	Indirect Effects of COVID-19 on Maternal, Neonatal, Child, Sexual and Reproductive Health Services in Kampala, Uganda	Uganda	Mothers & newborns	Country report	Greatest impacts from delayed health seeking, no public transports, HCWs disruptions; closures of health facilities for outpatients; decreased antenatal care impacts intermittent preventive treatment in pregnancy; visits for malaria in children decreased by 54%
16.	Chanda-Kapata et al., 2020 (26)	COVID-19 and malaria: A symptom screening challenge for malaria endemic countries	Africa	General population	Opinion paper	Health system disruptions; clinical aspects; importance of parallel testing; malaria commodities supply disruptions
17.	Chasaya M, 2020 (65)	An Update on Malaria trends in Zambia (2019 to 2020); A descriptive study	Zambia	General population	Country report	Increased malaria testing and cases

18.	Coker et al., 2021 (81)	Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa	sub-Sahara Africa	Children aged 0 to 19	Review	Malaria elimination is threatened by COVID-19
19.	Di Gennaro et al., 2020 (35)	Malaria and COVID-19: Common and Different Findings	General & SSA specific	General population	Opinion paper	Changed health seeking behavior disproportionately affects children; health system challenges; clinical aspects, co-infections
20.	Diongue and Diallo, 2020 (82)	COVID-19 during malaria transmission season in Africa and why we should be prepared: An example from Senegal	Senegal	General population	Opinion paper	Changed health seeking behavior; clinical aspects; COVID-19 and malaria management challenges
21.	Elliot Mbunge et al., 2021 (50) – pre-print	Impact of COVID-19 on Malaria Elimination: Juxtaposing Indoor Residual Spraying and Mobile Phones in Buhera Rural District, Zimbabwe	Zimbabwe	General population	Country report	IRS delays in 2020; increase in malaria cases (2981 in 2020, 1376 in 2019); disruptions of health services; antimalarial resistance problems; challenges for HCWs
22.	Emmanuel Awucha et al., 2020 (52)	Impact of the COVID-19 Pandemic on Consumers' Access to Essential Medicines in Nigeria	Nigeria	General population	Country report	Increase in alternative medicines uptake (10%) and prizes for antimalarials; supply chain disruptions; 74% reported less income during the pandemic; LMICs strongly depend on importations
23.	Gavi et al., 2021 (64)	Malaria incidence and mortality in Zimbabwe during the COVID-19 pandemic: analysis of routine surveillance data	Zimbabwe	General population	Country report	16% more malaria case and 38% more malaria cases than expected in 2020, probably following several malaria outbreaks
24.	Guerra et al., 2020 (57)	Malaria vector control in sub-Saharan Africa in the time of COVID-19: no room for complacency	sub-Sahara Africa	General population	Opinion paper	Clinical and diagnostical aspects; impacts on vector control measures; malaria campaign delays

25.	Hategeka et al., 2021 (63) – pre-print	Impact of the COVID-19 pandemic and response on the utilisation of health services during the first wave in Kinshasa, the Democratic Republic of the Congo	Democratic republic of the Congo	General population	Country report	20-90% reductions in health facility visits for malaria, depending on if the areas had a lockdown or not
26.	Hussein et al., 2020 (36)	Malaria and COVID-19: unmasking their ties	General & Africa specific	General population	Review	Hypothesis of causal link between antimalarials usage and low COVID-19 incidence; clinical aspects; challenges for malaria programs
27.	Inzaule et al., 2021 (83)	Genomic-informed pathogen surveillance in Africa: opportunities and challenges	Africa	General population	Opinion paper	Benefits for malaria from genomics-based surveillance strategy for COVID-19
28.	Kangbai et al., 2021 (47)	Re-reading ACT, BCG, and Low COVID-19 in Africa	Africa	General population	Opinion paper	Hypothesis: low COVID-19 incidence due to antimalarial usage and malaria antibodies
29.	Kusotera and Nhengu, 2020 (27)	Coronavirus-19 and malaria: The great mimics	Zimbabwe	General population	Country report	Concerns of false positive SARS-CoV-2 Ag-RDTs in malaria infected persons; increase in malaria cases in 2020 (44.7%); overlapping clinical aspects; health system challenges
30.	Makanjuola et al., 2020 (84)	COVID-19 and malaria in sub-Saharan Africa: Holistic diagnostic approaches may promote effective clinical case management	sub-Saharan Africa	General population	Review	Importance of parallel testing for SARS-CoV-2 and malaria; clinical and health system difficulties
31.	Menelas and Sabin, 2021 (71) – pre-print	Malaria or COVID-19? A case report highlighting a diagnostic challenge in Africa	Rwanda	40 years old women	Case report	Difficult diagnosis of malaria-COVID-19 co-infection
32.	Mvumbi, 2020 (85)	Mass intake of hydroxychloroquine or chloroquine in	General & Africa	General population	Opinion paper	Antimalarials uptake for COVID-19 affect

		the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings				malaria and resistance development
33.	Newby et al., 2021 (59)	Global health security requires endemic disease eradication	General & SSA	General population	Opinion paper	Over 90% of malaria campaigns undertaken in 2020; increase of health inequities; benefits of malaria eradication for COVID-19
34.	Nghochuzie et al., 2020 (49)	Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?	sub-Sahara Africa	General population	Opinion paper	Antimalarials resistances; RDTs supply shortages; increases of malaria cases and deaths in Zimbabwe and Cameroon; diagnostic challenges; changed health seeking and effects on children
35.	PMI U.S. president's malaria initiative, 2021 (86)	15 years of fighting malaria & saving lives, annual report to congress April 2021	Sub-Sahara Africa & Southeast Asia	General population	Report	Seasonal malaria chemoprevention for children in Sahel done with minimal delays; community approach for malaria prevention; difficult health care access (nearly 50% of the participants)
36.	Rahi et al., 2020 (79)	COVID-19 Mitigation Steps Provide a Blueprint for Malaria Control and Elimination	General & Africa	General population	Opinion paper	COVID-19 control lessons important for malaria management
37.	Rogerson et al., 2020 (51)	Identifying and combating the impacts of COVID-19 on malaria	General & Africa specific	General population	Opinion paper	Treatment disruptions; socio-economic aspects; challenges for HCWs; malaria product disruptions; health system challenges, malaria surveillance problems

38.	Rosenthal et al., 2020 (87)	COVID-19: Shining the Light on Africa	sub-Sahara Africa	General population	Opinion paper	Financial aspects; antimalarials shortages
39.	Sherrard-Smith et al., 2020 (23)	The potential public health consequences of COVID-19 on malaria in Africa	sub-Sahara Africa	General population	Modelling study	Malaria deaths in 2020 could double; impacts of ITN and antimalarials disruptions; benefits of seasonal malaria chemoprevention, mass drug administration, presumptive malaria treatment
40.	Shi et al., 2021 (55)	Assessing the syndemic of COVID-19 and malaria intervention in Africa	sub-Sahara Africa (Ethiopia, Nigeria, Tanzania, Zambia)	General population	Modelling study	Greatest impact on malaria health services if COVID-19 waves and main malaria season overlap
41.	Steketee et al., 2021 (31)	World Malaria Day 2021: Commemorating 15 Years of Contribution by the United States President's Malaria Initiative	General & Africa	General population	Opinion paper	Nearly all malaria campaigns undertaken despite the pandemic; disruptions of malaria testing, and treatment; excess malaria deaths could exceed COVID-19 deaths in some regions
42.	The Alliance for Malaria Prevention, 2020 (58)	2020 Annual Report	General & Africa	General population	Report	74% of planned ITNs distributed
43.	The Global Fund, 2021 (88)	Mitigating the impact of COVID-19 on countries affected by HIV, tuberculosis and malaria	General & Africa	General population	Report	About 75% of malaria programs reported disruptions; large financial resources needed
44.	The Global Fund, 2021 (32)	The impact of COVID-19 on HIV, TB and malaria services and systems for health: A snapshot from 502 health facilities across Africa and Asia	Africa & Asia	General population	Report	Up to 115 million people in extreme poverty; fear of COVID-19 infection in health facilities as main reason for reduced outpatient visits; malaria diagnosis and treatment reduced by 17% and 15% respectively; antimalarials stockouts (21% of

						all health facilities), lack of PPE (64%), deficits in COVID-19 testing capacities, lack of malaria treatments (40%)
45.	Velavan et al., 2021 (70)	COVID-19 and syndemic challenges in 'Battling the Big Three': HIV, TB and malaria	General & Africa	General population	Review	Increased malaria cases in many countries, suspended vector control activities
46.	Wang et al., 2020 (69)	Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic	Africa	General population	Opinion paper	Measures to reduce malaria support the COVID-19 response; health system challenges
47.	Weiss et al., 2021 (21)	Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis	Africa	General population	Modelling study	Antimalarials disruptions with greater impact on malaria incidence and deaths than ITNs; great variability between countries
48.	WHO, 2020a (22)	The potential impact of health service disruptions on the burden of malaria: a modelling analysis for countries in sub-Saharan Africa	sub-Sahara Africa	General population	Modelling study	Importance of ITNs; impacts on malaria burden following ITN and antimalarials shortages; worst case scenario: 769,000 deaths (743,000 in SSA), 70% in children under 5
49.	WHO, 2020b (30)	Tailoring malaria interventions in the COVID-19 response	General & Africa	General population	Policy guideline	Mass drug administration or presumptive treatment of malaria; adaptation of malaria interventions
50.	WHO, 2020c (17)	World malaria report 2020: 20 years of global progress & challenges, chapter 10	General & SSA specific	General population	Report and modelling study	Disruptions of malaria health services; delays of malaria programs; changed health seeking; adaptation of malaria programs & guidelines; malaria product shortages; 100,000 additional deaths

						if 50% antimalarials disruptions
51.	Zawawi et al., 2020 (68)	The impact of COVID-19 pandemic on malaria elimination	General & Africa	General population	Review	COVID-19 challenges Africa's weak health system; increase in malaria cases; indirect social effects, malaria outbreak in Zimbabwe during the lockdown; clinical challenges

424

425 Appendix 3: Bibliography

- 426 1. Dawood FS, Ricks P, Njie GJ, Daugherty M, Davis W, Fuller JA, et al. Observations
427 of the global epidemiology of COVID-19 from the prepandemic period using web-based
428 surveillance: a cross-sectional analysis. *The Lancet Infectious Diseases*. 2020;20(11):1255-
429 62.
- 430 2. Müller O, Lu G, Jahn A, Razum O. COVID-19 Control: Can Germany Learn From
431 China? *Int J Health Policy Manag*. 2020;9(10):432-5.
- 432 3. WHO Coronavirus (COVID-19) Dashboard [Internet]. World Health Organization, .
433 2021. Available from: <https://covid19.who.int/table>.
- 434 4. Lu G, Razum O, Jahn A, Zhang Y, Sutton B, Sridhar D, et al. COVID-19 in Germany
435 and China: mitigation versus elimination strategy. *Glob Health Action*. 2021;14(1):1875601.
- 436 5. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa.
437 *Science*. 2021;371(6524):27-8.
- 438 6. Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong
439 JN. COVID-19 in Africa: the spread and response. *Nat Med*. 2020;26(7):999-1003.
- 440 7. Boum Y, Bebell LM, Bissecck A-CZ-K. Africa needs local solutions to face the
441 COVID-19 pandemic. *The Lancet*. 2021;397(10281):1238-40.

- 442 8. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first
443 and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. *The Lancet*.
444 2021;397(10281):1265-75.
- 445 9. WHO. Coronavirus (COVID-19), Africa2021. Available from:
446 <https://www.afro.who.int/health-topics/coronavirus-covid-19>.
- 447 10. Gutman JR, Lucchi NW, Cantey PT, Steinhardt LC, Samuels AM, Kamb ML, et al.
448 Malaria and Parasitic Neglected Tropical Diseases: Potential Syndemics with COVID-19?
449 *Am J Trop Med Hyg*. 2020;103(2):572-7.
- 450 11. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al.
451 Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster
452 sample survey. *The Lancet Global Health*. 2021.
- 453 12. Usuf E, Roca A. Seroprevalence surveys in sub-Saharan Africa: what do they tell us?
454 *Lancet Glob Health*. 2021.
- 455 13. Impouma B, Wolfe CM, Mboussou F, Farham B, Saturday T, Pervilhac C, et al.
456 Monitoring and Evaluation of COVID-19 response in the WHO African Region: challenges
457 and lessons learned. *Epidemiol Infect*. 2021:1-14.
- 458 14. Müller O. Malaria in Africa: challenges for control and elimination in the 21st century:
459 Peter Lang Frankfurt; 2011.
- 460 15. Global Burden of Disease, Viz Hub [Internet]. University of Washington. 2021 [cited
461 30.04.2021]. Available from: <https://vizhub.healthdata.org/gbd-compare/>.
- 462 16. Amimo F, Lambert B, Magit A. What does the COVID-19 pandemic mean for HIV,
463 tuberculosis, and malaria control? *Trop Med Health*. 2020;48:32.
- 464 17. WHO. World malaria report 2020: 20 years of global progress and challenges.2020
465 11.05.2020. Available from: [https://www.who.int/teams/global-malaria-](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020)
466 [programme/reports/world-malaria-report-2020](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020).

- 467 18. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic
468 review or scoping review? Guidance for authors when choosing between a systematic or
469 scoping review approach. *BMC Medical Research Methodology*. 2018;18(1):143.
- 470 19. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
471 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*.
472 2018;169(7):467-73.
- 473 20. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO
474 framework to improve searching PubMed for clinical questions. *BMC Med Inform Decis*
475 *Mak*. 2007;7:16.
- 476 21. Weiss DJ, Bertozzi-Villa A, Rumisha SF, Amratia P, Arambepola R, Battle KE, et al.
477 Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and
478 mortality in Africa: a geospatial modelling analysis. *Lancet Infect Dis*. 2020.
- 479 22. WHO. The potential impact of health service disruptions on the burden of malaria: a
480 modelling analysis for countries in sub-Saharan Africa. 2020.
- 481 23. Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, et al.
482 The potential public health consequences of COVID-19 on malaria in Africa. *Nat Med*.
483 2020;26(9):1411-6.
- 484 24. Bell D, Hansen KS. Relative burdens of the COVID-19, malaria, tuberculosis and
485 HIV/AIDS epidemics in sub-Saharan Africa. *medRxiv*. 2021:2021.03.27.21254483.
- 486 25. Ansumana R, Sankoh O, Zumla A. Effects of disruption from COVID-19 on
487 antimalarial strategies. *Nat Med*. 2020;26(9):1334-6.
- 488 26. Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: A symptom screening
489 challenge for malaria endemic countries. *Int J Infect Dis*. 2020;94:151-3.
- 490 27. Kusotera T, Nhengu TG. Coronavirus-19 and malaria: The great mimics. *Afr J Prim*
491 *Health Care Fam Med*. 2020;12(1):e1-e3.

- 492 28. Ajayi IO, Ajumobi OO, Falade C. Malaria and COVID-19: commonalities,
493 intersections and implications for sustaining malaria control. *The Pan African medical*
494 *journal*. 2020;37(Suppl 1):1.
- 495 29. Buonsenso D, Iodice F, Cinicola B, Raffaelli F, Sowa S, Ricciardi W. Management of
496 malaria in children under 5-years-old during COVID-19 pandemic in Sierra Leone: a lesson
497 learned? *medRxiv*. 2020:2020.11.04.20225714.
- 498 30. WHO. Tailoring malaria interventions in the COVID-19 response. *Global Malaria*
499 *Programme* [Internet]. 2020 05.04.2021. Available from:
500 [https://www.who.int/publications/m/item/tailoring-malaria-interventions-in-the-covid-19-](https://www.who.int/publications/m/item/tailoring-malaria-interventions-in-the-covid-19-response)
501 [response](https://www.who.int/publications/m/item/tailoring-malaria-interventions-in-the-covid-19-response).
- 502 31. Steketee RW, Choi M, Linn A, Florey L, Murphy M, Panjabi R. World Malaria Day
503 2021: Commemorating 15 Years of Contribution by the United States President's Malaria
504 Initiative. *The American Journal of Tropical Medicine and Hygiene*. 2021.
- 505 32. The Global Fund. THE IMPACT OF COVID-19 ON HIV, TB AND MALARIA
506 SERVICES AND SYSTEMS FOR HEALTH: A SNAPSHOT FROM 502 HEALTH
507 FACILITIES ACROSS AFRICA AND ASIA2021. Available from:
508 [https://www.theglobalfund.org/en/updates/other-updates/2021-04-13-the-impact-of-covid-19-](https://www.theglobalfund.org/en/updates/other-updates/2021-04-13-the-impact-of-covid-19-on-hiv-tb-and-malaria-services-and-systems-for-health/)
509 [on-hiv-tb-and-malaria-services-and-systems-for-health/](https://www.theglobalfund.org/en/updates/other-updates/2021-04-13-the-impact-of-covid-19-on-hiv-tb-and-malaria-services-and-systems-for-health/).
- 510 33. Brooke B, Raman J, Frean J, Rundle K, Maartens F, Misiani E, et al. Implementing
511 malaria control in South Africa, Eswatini and southern Mozambique during the COVID-19
512 pandemic. *SAMJ: South African Medical Journal*. 2020;110(11):1072-6.
- 513 34. Anjorin AA, Abioye AI, Asowata OE, Soipe A, Kazeem MI, Adesanya IO, et al.
514 Comorbidities and the COVID-19 Pandemic Dynamics in Africa. *Trop Med Int Health*. 2020.
- 515 35. Di Gennaro F, Marotta C, Locantore P, Pizzol D, Putoto G. Malaria and COVID-19:
516 Common and Different Findings. *Trop Med Infect Dis*. 2020;5(3).

- 517 36. Hussein MIH, Albashir AAD, Elawad OAMA, Homeida A. Malaria and COVID-19:
518 unmasking their ties. *Malaria journal*. 2020;19(1):457.
- 519 37. Beshir KB, Grignard L, Hajissa K, Mohammed A, Nurhussein AM, Ishengoma DS, et
520 al. Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the COVID-
521 19 Pandemic? *Am J Trop Med Hyg*. 2020;103(2):558-60.
- 522 38. Abdul-Mumin A, Abubakari A, Agbozo F, Abdul-Karim A, Nuertey BD, Mumuni K,
523 et al. Field evaluation of specificity and sensitivity of a standard SARS-CoV-2 antigen rapid
524 diagnostic test: A prospective study at a teaching hospital in Northern Ghana. *medRxiv*.
525 2021:2021.06.03.21258300.
- 526 39. Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, et al. Anti-SARS-CoV-2 Potential of
527 Artemisinins In Vitro. *ACS Infect Dis*. 2020;6(9):2524-31.
- 528 40. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on
529 the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care*.
530 2020;57:279-83.
- 531 41. Gendrot M, Dufлот I, Boxberger M, Delandre O, Jardot P, Le Bideau M, et al.
532 Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In
533 vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. *Int J Infect Dis*.
534 2020;99:437-40.
- 535 42. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al.
536 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology*.
537 2005;2:69-.
- 538 43. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et
539 al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
540 *New England Journal of Medicine*. 2020;383(6):517-25.

- 541 44. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al.
542 Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New
543 England Journal of Medicine. 2020;383(21):2041-52.
- 544 45. Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E. From
545 hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to
546 combat SARS-CoV-2? J Travel Med. 2021;28(2).
- 547 46. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in
548 patients with mainly mild to moderate coronavirus disease 2019: open label, randomised
549 controlled trial. BMJ. 2020;369:m1849.
- 550 47. Kangbai JB, Sao Babawo L, Kaitibi D, Sandi AA, George AM, Sahr F. Re-reading
551 ACT, BCG, and Low COVID-19 in Africa. SN comprehensive clinical medicine.
552 2021;3(1):11-5.
- 553 48. Aborode AT, David KB, Uwishema O, Nathaniel AL, Imisioluwa JO, Onigbinde SB,
554 et al. Fighting COVID-19 at the Expense of Malaria in Africa: The Consequences and Policy
555 Options. Am J Trop Med Hyg. 2020.
- 556 49. Nghochuzie NN, Olwal CO, Udoakang AJ, Amenga-Etego LN, Amambua-Ngwa A.
557 Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the
558 Future of Malaria Bleak? Front Microbiol. 2020;11:1476.
- 559 50. Mbunge E, Millham R, Sibiyana MN, Takavarasha S. Impact of COVID-19 on Malaria
560 Elimination: Juxtaposing Indoor Residual Spraying and Mobile Phones in Buhera Rural
561 District, Zimbabwe. 2021.
- 562 51. Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, et al.
563 Identifying and combating the impacts of COVID-19 on malaria. BMC Med. 2020;18(1):239.
- 564 52. Emmanuel Awucha N, Chinelo JaneFrances O, Chima Meshach A, Chiamaka
565 Henrietta J, Ibilolia Daniel A, Esther Chidiebere N. Impact of the COVID-19 Pandemic on

- 566 Consumers' Access to Essential Medicines in Nigeria. *Am J Trop Med Hyg.*
567 2020;103(4):1630-4.
- 568 53. Amimo F, Lambert B, Magit A, Hashizume M. The potential impact of the COVID-19
569 pandemic on HIV, tuberculosis, and malaria control in Africa: a systematic review of
570 modelling studies and population surveys. 2020.
- 571 54. Aïkpon R, Affoukou C, Hounpkatin B, Eclou DD, Cyaka Y, Egwu E, et al. Digitalized
572 mass distribution campaign of insecticide-treated nets (ITNs) in the particular context of
573 Covid-19 pandemic in Benin: challenges and lessons learned. *Malar J.* 2020;19(1):431.
- 574 55. Shi B, Zheng J, Xia S, Lin S, Wang X, Liu Y, et al. Accessing the syndemic of
575 COVID-19 and malaria intervention in Africa. 2020.
- 576 56. Baral S, Rao A, Twahirwa Rwema JO, Lyons C, Cevik M, Kågesten AE, et al.
577 Competing Health Risks Associated with the COVID-19 Pandemic and Response: A Scoping
578 Review. *medRxiv.* 2021:2021.01.07.21249419.
- 579 57. Guerra CA, Tresor Donfack O, Motobe Vaz L, Mba Nlang JA, Nze Nchama LO, Mba
580 Eyono JN, et al. Malaria vector control in sub-Saharan Africa in the time of COVID-19: no
581 room for complacency. *BMJ Glob Health.* 2020;5(9).
- 582 58. The Alliance for Malaria Prevention. 2020 Annual Report2020. Available from:
583 [https://allianceformalariaprevention.com/wp-content/uploads/2021/03/FINAL-AMP-Annual-](https://allianceformalariaprevention.com/wp-content/uploads/2021/03/FINAL-AMP-Annual-Report-2020.pdf)
584 [Report-2020.pdf](https://allianceformalariaprevention.com/wp-content/uploads/2021/03/FINAL-AMP-Annual-Report-2020.pdf).
- 585 59. Newby G, Mpanju-Shumbusho W, Feachem RGA. Global health security requires
586 endemic disease eradication. *The Lancet.* 2021;397(10280):1163-5.
- 587 60. RBM Partnership to end malaria. RBM Partnership to End Malaria position on the
588 next Global Fund strategy2020. Available from:
589 [https://endmalaria.org/sites/default/files/RBM%20Position%20Statement%20on%20Global%](https://endmalaria.org/sites/default/files/RBM%20Position%20Statement%20on%20Global%20Fund%27s%20Strategy.pdf)
590 [20Fund%27s%20Strategy.pdf](https://endmalaria.org/sites/default/files/RBM%20Position%20Statement%20on%20Global%20Fund%27s%20Strategy.pdf).

- 591 61. Bell D, Hansen KS, Kiragga AN, Kambugu A, Kissa J, Mbonye AK. Predicting the
592 Impact of COVID-19 and the Potential Impact of the Public Health Response on Disease
593 Burden in Uganda. *Am J Trop Med Hyg.* 2020;103(3):1191-7.
- 594 62. Burt J, Ouma J, Amone A, Aol L, Sekikubo M, Nakimuli A, et al. Indirect Effects of
595 COVID-19 on Maternal, Neonatal, Child, Sexual and Reproductive Health Services in
596 Kampala, Uganda. *medRxiv.* 2021:2021.04.23.21255940.
- 597 63. Hategeka C, Carter SE, Chenge FM, Katanga EN, Lurton G, Mayaka SM-N, et al.
598 Impact of the COVID-19 pandemic and response on the utilisation of health services during
599 the first wave in Kinshasa, the Democratic Republic of the Congo. *medRxiv.*
600 2021:2021.04.08.21255096.
- 601 64. Gavi S, Tapera O, Mberikunashe J, Kanyangarara M. Malaria incidence and mortality
602 in Zimbabwe during the COVID-19 pandemic: analysis of routine surveillance data. *Malar J.*
603 2021;20(1):233.
- 604 65. Chasaya M PM, Ngomah MA. An Update on Malaria trends in Zambia (2019 to
605 2020); A descriptive study. *Health Press Zambia Bull.* 2020:13-8.
- 606 66. Müller O, Razum O, Jahn A. Effects of non-pharmaceutical interventions against
607 COVID-19 on the incidence of other diseases. *The Lancet Regional Health – Europe.* 2021;6.
- 608 67. Abbas K, Mogasale V. Disruptions to childhood immunisation due to the COVID-19
609 pandemic. *The Lancet.*
- 610 68. Zawawi A, Alghanmi M, Alsaady I, Gattan H, Zakai H, Couper K. The impact of
611 COVID-19 pandemic on malaria elimination. *Parasite Epidemiology and Control.*
612 2020;11:e00187.
- 613 69. Wang J, Xu C, Wong YK, He Y, Adegnika AA, Kremsner PG, et al. Preparedness is
614 essential for malaria-endemic regions during the COVID-19 pandemic. *Lancet.*
615 2020;395(10230):1094-6.

- 616 70. Velavan TP, Meyer CG, Esen M, Kremsner PG, Ntoumi F, Consortium P-I-NC.
617 COVID-19 and syndemic challenges in & lsquo;Battling the Big Three & rsquo;: HIV, TB
618 and malaria. *International Journal of Infectious Diseases*. 2021;106:29-32.
- 619 71. Nkeshimana M, Nsanzimana S. Malaria or COVID-19? A case report highlighting a
620 diagnostic challenge in Africa. 2021.
- 621 72. Achan Jane SA, Wanzira Humphrey, Kyagulanyi Tonny, Nuwa Anthony, Magumba
622 Godfrey, Kusasira Stephen, Sewanyana Isaac, Tetteh Kevin, Drakeley Chris, Nakwagala
623 Fredrick, Aanyu Helen, Opigo Jimmy, Hamade Prudence, Marasciulo Madeleine, Batera
624 Byarugaba, Tibenderana, James, . Impact of Current Malaria Infection and Previous Malaria
625 Exposure on the Clinical Profiles and Outcome of COVID-19 in a High Malaria Transmission
626 Setting: A Prospective Cohort Study. *The Lancet pre-prints SSRN*. 2021.
- 627 73. C Coban KJI, T Kawai, H Hemmi, S Sato, S Uematsu, Frosch AE, John CC.
628 Immunomodulation in *Plasmodium falciparum* malaria: experiments in nature and their
629 conflicting implications for potential therapeutic agents. *Expert review of anti-infective*
630 *therapy*. 2005;201.
- 631 74. Thompson MG, Breiman RF, Hamel MJ, Desai M, Emukule G, Khagayi S, et al.
632 Influenza and Malaria Coinfection Among Young Children in Western Kenya, 2009–2011.
633 *The Journal of Infectious Diseases*. 2012;206(11):1674-84.
- 634 75. Edwards CL, Zhang V, Werder RB, Best SE, Sebina I, James KR, et al. Coinfection
635 with Blood-Stage *Plasmodium* Promotes Systemic Type I Interferon Production during
636 Pneumovirus Infection but Impairs Inflammation and Viral Control in the Lung. *Clinical and*
637 *Vaccine Immunology*. 2015;22(5):477-83.
- 638 76. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al.
639 Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-
640 income and middle-income countries: a modelling study. *Lancet Glob Health*.
641 2020;8(9):e1132-e41.

- 642 77. Figueroa JP, Bottazzi ME, Hotez P, Batista C, Ergonul O, Gilbert S, et al. Urgent
643 needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
644 The Lancet. 2021;397(10274):562-4.
- 645 78. The Lancet Infectious D. The rocky road to universal COVID-19 vaccination. The
646 Lancet Infectious Diseases. 2021;21(6):743.
- 647 79. Rahi M, Das P, Sharma A. COVID-19 Mitigation Steps Provide a Blueprint for
648 Malaria Control and Elimination. Am J Trop Med Hyg. 2020;103(1):28-30.
- 649 80. Buonsenso D, Cinicola B, Kallon MN, Iodice F. Child Healthcare and Immunizations
650 in Sub-Saharan Africa During the COVID-19 Pandemic. Front Pediatr. 2020;8:517.
- 651 81. Coker M, Folayan MO, Michelow IC, Oladokun RE, Torbunde N, Sam-Agudu NA.
652 Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-
653 Saharan Africa. Pediatr Res. 2020.
- 654 82. Diongue K, Diallo MA. COVID-19 during malaria transmission season in Africa and
655 why we should be prepared: An example from Senegal. African Journal of Laboratory
656 Medicine. 2020;9(1):3.
- 657 83. Inzaule SC, Tessema SK, Kebede Y, Ouma AEO, Nkengasong JN. Genomic-informed
658 pathogen surveillance in Africa: opportunities and challenges. The Lancet Infectious
659 Diseases. 2021.
- 660 84. Makanjuola RO, Ishaleku D, Taylor-Robinson A. COVID-19 and malaria in sub-
661 saharan Africa: Holistic diagnostic approaches may promote effective clinical case
662 management. Microbes and Infectious Diseases. 2020;1(3):100-6.
- 663 85. Mvumbi DM. Mass intake of hydroxychloroquine or chloroquine in the present
664 context of the Covid-19 outbreak: Possible consequences in endemic malaria settings. Med
665 Hypotheses. 2020;143:109912.
- 666 86. P.M.I. US President's malaria initiative. U.S. President's Malaria Initiative Burkina
667 Faso Malaria Operational Plan FY 20202020. Available from: www.pmi.gov.

- 668 87. Rosenthal PJ, Breman JG, Djimde AA, John CC, Kanya MR, Leke RGF, et al.
669 COVID-19: Shining the Light on Africa. *Am J Trop Med Hyg.* 2020;102(6):1145-8.
- 670 88. The Global Fund. MITIGATING THE IMPACT OF COVID-19 ON COUNTRIES
671 AFFECTED BY HIV, TUBERCULOSIS AND MALARIA2020. Available from:
672 https://www.theglobalfund.org/media/9819/covid19_mitigatingimpact_report_en.pdf.
673
674